Consequences of coagulation in health and disease: The use of fluorescent markers
Ebba Biotech welcomes you to listen to Prof. Resia Pretorius present her research findings using the Amytracker molecules. Her presentation titled “Consequences of coagulation in health and disease: The use of fluorescent markers” will detail past work with the Amytracker molecules within her group and her new exciting work with Long Covid patients.
DISCLAIMER: Prof. Pretorius presentation is purely research based and for informational purposes only. This presentation contains no clinical advice for patients. If you have any health issues please contact your healthcare providers.
Opto-electronically active Materials for Infection Detection and Control
Ebba Biotech welcomes you to listen to our resident expert from the Center for the Advancement of the Integrated Medical and Engineering Sciences (AIMES) at Karolinska Institutet, Sweden - Dr. Susanne Löffler.
During this talk titled "Opto-electronically active Materials for Infection Detection and Control", Dr. Löffler will be presenting AIMES research about using optotracers for infection detection and control.
Read more about Dr. Löffler's work at AIMES here: https://aimes.se/
About Dr. Löffler
As a Group Leader at the Center for the Advancement of Integrated Medical and Engineering Sciences (AIMES) based in Stockholm, Sweden, Dr. Löffler specialises in Organic Bioelectronics for Bacterial Infection. Her background in biomedical sciences and signal processing make her uniquely suited to develop novel and specialised tools for data management, visualisation and analysis for bacterial detection technologies.
With an academic career starting at the University of Lübeck with both an MSc in Molecular Life Sciences and a PhD covering the specialisation in neural recordings and microstimulation, Dr. Löffler now spends her time bringing new exciting scientific applications to the commercial and entrepreneurial space. This being done through her work consulting life science start ups whilst still maintaining her position at AIMES.
Dr. Löffler describes research using optotracers. The optotracers described during the webinar are commercially available under the product family name EbbaBiolight, which are marketed and sold by Ebba Biotech.
Discovering an Antibiofilm Therapy for Urinary Tract Infections
Ebba Biotech welcomes you to listen to Dr. Ashraf Zarkan from University of Cambridge presenting his work on antibiofilm therapies for urinary tract infections using EbbaBiolight.
About the speaker: Ashraf Zarkan is a microbiologist with a pharmaceutical background, holding a PhD in Biochemistry from the University of Cambridge. He did his bachelor’s degree in Pharmacy and Pharmaceutical Chemistry followed by an MSc in Microbiology. He has a broad repertoire of training skills that range from experimental research to computational approaches to data analysis. Ash is passionate about tackling the increasing problem with antibiotic resistance, and his research has been focused on developing antibiotic adjuvants. He has a solid experience in bacterial signalling and antibiotic action, side effects, and combinations with adjuvants.
Abstract: Serious bacterial infections represent an unprecedented worldwide threat, due mainly to the emergence of antibiotic-resistant bacteria for which we have limited therapies. Antibiotic resistance is on the rise and has recently been identified as one of the World Health Organization’s global health challenges in the next decade. A key aspect of the antibiotic resistance problem is the ability of bacteria to form biofilms, which provide protection from both antibiotics and the host immune system. Biofilms are implicated in chronic infections such as urinary tract infections (UTIs). UTIs are among the most prevalent bacterial infections, affecting 150 million people per year worldwide, with 75% of infections occurring due to uropathogenic E. coli. Research by Dr Zarkan and his colleagues from the University of Cambridge highlighted the inhibition of an E. coli enzyme as a plausible route to inhibit biofilm formation, thereby reduce pathogenicity and increase antibiotic effectiveness in UTIs. In this webinar, you will learn how a collaboration between the University of Cambridge and Ebba Biotech AB successfully confirmed the antibiofilm properties of a set of novel inhibitors in clinical strains of uropathogenic E. coli. The current focus is in optimising these hits and completing pre-clinical development to be able to move further into clinical trials.
Optotracing for detection & quantification of Staphylococci
Ebba Biotech welcomes you to listen to Dr. Karen Butina present her research findings using EbbaBiolight-like molecules. This webinar will focus on the use of the Optotracer molecules and technology applied on Staphylococci bacteria. You can read more about Dr. Butina's work here. DISCLAIMER: Dr. Butina describes her work using HS-167 molecules. These are predecessor molecules to what is now commercialised under the product family name EbbaBiolight, which are marketed and sold by Ebba Biotech.
Originally from Slovenia, Dr. Butina received her Bachelor’s degree in Biotechnology in Ljubljana before pursuing her Masters and PhD at KI in Sweden. At KI she was part of the pioneering team (Prof. Richter Dahlfors Group) behind the Optotracer technology within microbiology. Her extensive background in interdisciplinary work has broadened her interests within the medical field and she continuously strives to find out how things work and develop applications to contribute to an equal society.
Cellulose in Cancer Diagnostics
Ebba Biotech welcomes you to listen to our newest webinar featuring Dr. Tharagan Kumar presenting his work from his time at KTH, the Royal Institute of Technology in Stockholm Sweden. During this talk titled “Cellulose in Cancer Diagnostics”, Dr. Kumar will be presenting his work breaking barriers in diagnostics using the Ebba Biotech Carbotrace molecules.
About Dr. Kumar
Dr. Kumar comes from a background in biotechnology on the nanoscale leading him to seek the link between science and technology in medicine. With this, his studies from bachelors level all the way to doctoral studies focused heavily on how modern technology can improve lives - and importantly - how to make it accessible. This has led him to seek opportunities within med-tech to understand each facet of the industry from concept, to funding to ultimately change lives.
Read more about Dr. Kumar and his research here: https://www.scilifelab.se/news/promising-diagnostic-tool-for-cancer-diagnostics/ Or about his publication here: https://www.ebbabiotech.com/blogs/carbotrace-publications/breaking-barriers-in-early-detection-of-cancer
Read more about Dr. Kumar and his research here: https://www.scilifelab.se/news/promising-diagnostic-tool-for-cancer-diagnostics/
Or about his publication here: https://www.ebbabiotech.com/blogs/carbotrace-publications/breaking-barriers-in-early-detection-of-cancer
Selective method for spectral identification and recovery of polysaccharides from biorefining
Ebba Biotech welcomes you to listen to Professor Ulrica Edlund from the Royal Institute of Technology (KTH) in Stockholm and her revolutionary work with Carbotrace and nano-materials.
The webinar titled "Selective method for spectral identification and recovery of polysaccharides from biorefining" explains how she uses Optotracers, like Carbotrace, in her research to discover and characterise renewable resources for biorefinement.
As a leading researcher in her field, Prof. Edlund contributes to reach UN sustainability goals by paving the way for a greener future moving towards renewable materials and circular economy. Her passion for finding sustainable solutions to maximise the potential of natural resources such as biomass has also led her to become the Vice Director of the research consortium AIMES (Centre for the Advancement of Integrated Medical and Engineering Sciences).